Literature DB >> 30359432

Preserved endothelial function in young adults with type 1 diabetes.

Martin Heier1,2,3, Cathrine Nygaard Espeland4, Cathrine Brunborg5, Ingebjørg Seljeflot2,6, Hanna Dis Margeirsdottir2,3,7, Kristian F Hanssen2,3,8, Drude Fugelseth2,4, Knut Dahl-Jørgensen1,2,3.   

Abstract

BACKGROUND AND AIM: Endothelial dysfunction is involved in the pathogenesis of atherosclerosis and is typically present in older adults with type 1 diabetes (T1D). In young adults, we aimed to assess the impact of T1D on endothelial function as detected by digital peripheral arterial tonometry (PAT) and its relationship with cardiovascular risk factors and long term glycemic control.
MATERIALS AND METHODS: Reactive hyperemia index (RHI) as a measure of endothelial function was assessed by PAT in 46 T1D patients and 32 healthy controls. All were participants in the "Atherosclerosis and Childhood Diabetes" study, with baseline values registered five years previously. Annual measurements of HbA1c for assessment of glycemic burden were provided by the Norwegian Childhood Diabetes Registry.
RESULTS: The diabetes patients had a mean age of 20.8 years, a median duration of diabetes of 10.0 years and a mean HbA1c of 8.7%. RHI was not significantly decreased in the diabetes group, mean 2.00 (SD = 0.59) vs. 2.21 (SD = 0.56), p = .116. There was no gender difference or any associations with traditional risk factors. Furthermore, there was no significant association between RHI and either HbA1c or long term glycemic burden.
CONCLUSIONS: RHI as a measure of endothelial function was preserved in young adults with T1D compared with healthy controls.

Entities:  

Year:  2018        PMID: 30359432      PMCID: PMC6201945          DOI: 10.1371/journal.pone.0206523

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Endothelial dysfunction is a frequent characteristic of early atherogenesis.[1, 2] Flow-mediated dilatation (FMD) has been the most widely used non-invasive method of assessing endothelial function. It reflects the bioavailability of endothelial-derived nitric oxide (NO),[3] and impaired FMD is associated with cardiovascular disease (CVD) events.[4, 5] FMD is, however, operator dependent and requires strict technical and methodological standardization.[6] Perhaps overcoming these limitations is a device that applies peripheral arterial tonometry (PAT), EndoPAT (Itamar Medical Ltd, Caesarea, Israel). EndoPAT requires less training and is largely automated. Sensors placed on each index finger measure changes in blood volume in the vasculature before and after a 5-minute occlusion of the brachial artery in the non-dominant arm. The contralateral arm serves as a control, facilitating adjustment for non-endothelial dependent factors. The adjusted post-occlusion to pre-occlusion ratio, the reactive hyperemia index (RHI), is calculated. RHI has been shown to correlate well with invasive measurement of coronary endothelial function,[7] predict adverse cardiovascular events in a 7-year follow-up study[8] and was associated with conventional risk factors in a community-based cohort of adults.[9] As with FMD, changes in RHI are also largely mediated by NO.[10] Despite this, a majority of studies show a poor correlation between FMD and RHI, suggesting that they provide different and unique information about vasoreactivity.[11-16] Patients with type 1 diabetes (T1D) are prone to accelerated atherosclerosis, leading to increased morbidity and mortality from CVD.[17, 18] There is, however, insufficient knowledge about the early phases of atherosclerosis, partially due to the lack of clinically useful non-invasive techniques to precisely assess the subclinical stage. Endothelial function is frequently impaired in adult patients with T1D.[19] In children and adolescents with T1D, most, but not all studies of FMD have demonstrated reduced endothelial function in patients with T1D compared with healthy control subjects.[20-24] Studies applying RHI in this age group have also largely shown reduced values in patients with T1D.[25-27] None of these studies were longitudinal. We hypothesized that T1D would negatively affect endothelial function. We aimed to test our hypothesis by assessing the impact of T1D on endothelial function as detected by PAT and its relationship with cardiovascular risk factors and long term glycemic control.

Materials and methods

Study population

The baseline examinations in the population-based "Atherosclerosis and Childhood Diabetes" study were performed from 2006–2008.[28] As part of the 5-year follow-up, 2011–2013, participants above 18 years of age were invited to take part in the present sub-study. Among the healthy control subjects, 17 had baseline values and 15 were recruited in the 5-year follow-up. In order to isolate the effect of T1D in early atherosclerosis, exclusion criteria were smoking, pregnancy, current infectious disease, hypertension (above 90th percentile), chronic diseases other than diabetes or any kind of long term medication. The diabetes patients all received intensified insulin injection treatment (> 4 daily injections) or used insulin pumps from the time of diagnosis. None had overt retinopathy or nephropathy. A total of 46 diabetes patients and 32 controls were included. They all gave their written informed consent. The protocol was approved by the Norwegian Regional Committee for Research Ethics, and the study was conducted according to the Declaration of Helsinki.

Laboratory analyses

All examinations were performed after an overnight fast. The baseline clinical examination has been described previously,[28] and baseline data was available for all diabetes patients and 17 of the controls. Annual HbA1c values from 2000 to 2012 were obtained from the Norwegian Childhood Diabetes Registry, and they were all measured at the same DCCT-standardized laboratory using high performance liquid chromatography (Variant; Bio-Rad, Richmond, CA, USA), the inter-assay coefficient of variation (CV) < 3%. Each patient had on average 8 annual HbA1c measurements (range 3–12), and these were used to calculate mean HbA1c at baseline and follow-up. Diabetes duration multiplied by mean HbA1c at each time point provided an estimate of glycemic burden. Routine laboratory analyses were performed by conventional methods.

Endothelial function

Digital PAT was performed using EndoPAT 2000 (Itamar Medical Ltd, Caesarea, Israel) as part of the 5-year follow-up of the "Atherosclerosis and Childhood Diabetes" study. The patients were examined in the supine position on a bed in a quiet and dimly lit room. Plethysmographic bio-sensors were placed on the index finger of both hands. From these, arterial pulsatile volume changes were recorded. After registering a five minute baseline signal, a brachial blood pressure cuff on the non-dominant upper arm was inflated to approximately 200 mmHg for exactly five minutes. This period of ischemia resulted in vasodilation followed by reactive hyperemia when blood flow returned. The PAT signal was recorded for another five minutes. A post-occlusion to pre-occlusion ratio was calculated by the EndoPAT software, resulting in a reactive hyperemia index. An RHI score of 1.67 and below is considered abnormal, and a score above 2.00 is recommended.[7]

Statistical analysis

Demographic and clinical data are presented as either proportions, means with their standard deviations (SD) or medians with the 25th and 75th percentile. Differences in continuous variables between groups were tested with the Student t-test for normally distributed data, alternatively the Mann-Whitney U-test for non-normally distributed data. Correlation analyses between continuous variables were performed using Pearson’s correlation coefficient (r) or Spearman’s rho (ρ) when appropriate. Univariate linear regression analysis was performed to study the association between current conventional risk factors (systolic blood pressure, diastolic blood pressure, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apolipoprotein B, apolipoprotein A-I, HbA1c, waist circumference, body mass index (BMI) and diabetes duration) as exposure variables with RHI as the outcome variable. To identify possible confounders, we studied all variables that could influence the outcome. Only variables with significant relationships with both the exposure and the outcome variables were considered as possible confounders and included in a multivariate analysis. Adjustment for multiple confounding factors was done using multivariate linear regression analysis with a manual backward elimination procedure. A significance level of 5% was used. All statistical analyses were performed using the SPSS software package for Mac, version 19.0 (SPSS, Chicago, IL).

Results

The clinical and metabolic characteristics of the participants are shown in Table 1. The diabetes patients had greater waist circumference compared with the controls, as well as higher HbA1c and apolipoprotein B. At baseline they also had higher BMI, total cholesterol, LDL cholesterol and apolipoprotein A-I. The participants in both groups had otherwise similar characteristics.
Table 1

Clinical and metabolic characteristics.

Baseline5-year follow-up
DiabetesControlsp-valueDiabetesControlsp-value
n46174632
Diabetes duration (years)15.3 (3.4, 9.6)10.0 (8.1, 14.3)
Insulin pump users n (%)20 (43.5)23 (50.0)
Age (years)16.0 (1.8)15.4 (2.0).28620.8 (1.8)21.1 (1.9).519
Girls, n (%)22 (47.8)9 (52.9).71822 (47.8)17 (53.1).645
Height (cm)170.4 (8.9)170.3 (7.8).940174.5 (8.5)175.3 (9.1).688
Weight (kg)66.5 (15.0)59.0 (12.2).07078.8 (15.3)72.6 (15.0).080
BMI (kg/m2)121.6 (19.6, 25.4)19.0 (17.9, 23.7).01723.9 (22.6, 28.1)22.7 (20.5, 26.0).037
Waist circumference (cm)76.5 (9.8)69.5 (6.4).00384.1 (10.5)78.0 (10.1).012
Systolic blood pressure (mmHg)105.2 (11.0)104.6 (10.8).866115.8 (11.5)114.6 (8.9).616
Diastolic blood pressure (mmHg)62.2 (9.6)60.5 (6.2).52070.0 (8.9)69.9 (7.4).943
Pulse pressure43.0 (7.6)44.1 (9.3).63145.7 (9.2)44.7 (8.9).605
HbA1c (%)8.2 (1.1)5.3 (0.3)< .0018.7 (1.4)5.2 (0.3)< .001
Mean HbA1c (%)7.9 (1.1)8.3 (1.0)
Glycemic burden (% x years)52.3 (34.9)94.0 (36.3)
Total cholesterol (mmol/L)4.5 (0.7)4.0 (0.7).0144.8 (1.0)4.5 (0.9).138
HDL cholesterol (mmol/L)1.7 (0.4)1.6 (0.4).3251.6 (0.4)1.6 (0.5).914
LDL cholesterol (mmol/L)2.5 (0.6)2.1 (0.6).0422.7 (0.8)2.5 (0.7).150
Triglycerides (mmol/L)10.7 (0.6, 0.8)0.6 (0.4, 0.7).2481.0 (0.7, 1.4)1.0 (0.7, 1.5).681
Apolipoprotein B (g/L)0.74 (0.16)0.60 (0.13).0020.92 (0.23)0.81 (0.20).041
Apolipoprotein A-I (g/L)1.44 (0.24)1.18 (0.38).0211.56 (0.32)1.55 (0.35).936
Urine Albumin/Creatinine (mg/mmol)10.50 (0.30, 1.28)0.77 (0.35, 1.64).6690.56 (0.24, 1.25)0.30 (0.14, 0.99).405
Reactive Hyperemia Index (RHI)2.00 (0.59)2.21 (0.56).116

Mean values (SD).

1 Median (25th and 75th percentile).

Mean values (SD). 1 Median (25th and 75th percentile). RHI tended to be lower in the diabetes group compared with controls, but the difference was not significant, mean 2.00 (SD = 0.59) vs. 2.21 (SD = 0.56), p = .116. We found no significant difference between the genders among all participants (mean girls 2.08 (SD = 0.60) vs. boys 2.09 (SD = 0.57), p = .929), in the diabetes group (mean girls 2.01 (SD = 0.59) vs. boys 1.99 (SD = 0.61), p = .888), or in the control group (mean girls 2.17 (SD = 0.62) vs. boys 2.26 (SD = 0.49), p = .646). There was no significant correlation between RHI and HbA1c, mean HbA1c or glycemic burden, either at baseline or at the 5-year follow-up. RHI was not significantly associated with any current conventional cardiovascular risk factors in either group. Using the cut-off value recommended by the manufacturer of 1.67 to determine endothelial dysfunction, we found no significant difference between the groups, p = .447 (Fig 1).
Fig 1

Percentage of participants above and below RHI = 1.67.

Discussion

The main finding in our study was the lack of significant difference in RHI between young adult patients with T1D and healthy control subjects. This is in contrast to previous well conducted studies with similar sample size (44 and 23 patients with T1D, respectively).[25, 26] The participants in these studies, however, were slightly younger than in our study, and all had not completed puberty. Possibly, pubertal stage could explain these differences, as later studies in healthy children have shown that RHI increases during puberty.[29, 30] Difference in pubertal stage might also be the reason Mahmud et al. found lower values in boys with T1D compared with girls.[31] Pareyn et al., however, found lower values in girls with T1D.[27] This discrepancy may be due to chance, as we were unable to demonstrate any gender difference, in line with a larger study in healthy children.[32] As Fig 1 illustrates, 30.4% of the diabetes patients were below the cut-off value set by the manufacturer to indicate endothelial dysfunction. This was also the case for 21.9% of the controls, and there was no significant difference between the groups. Scaramuzza et al. have demonstrated considerably higher percentages (76.7% and 81.8%) in adolescents with T1D during one year of follow-up.[33] We find it unlikely that 21.9% of healthy young adults have impaired endothelial function. Thus, the relatively high number of abnormal values among both diabetes patients and control subjects suggests that the recommended cut-off value might not be ideal for cardiovascular risk assessment in this age group. In a cross-sectional study of middle-aged healthy volunteers, associations between RHI and male gender, BMI, total-/HDL-cholesterol, diabetes, smoking and lipid-lowering therapy were reported.[9] Also, in healthy adolescents RHI was associated with soluble intercellular adhesion molecule-1, insulin resistance and saturated fatty acids.[32] Contrary to this, smaller studies in healthy subjects[15, 30] and in young patients with T1D[25, 27] only showed significant associations with RHI and pubertal stage. In our study, there were no significant associations between traditional cardiovascular risk factors and RHI in either group. These disparities are likely due to differences in sample size. Previous studies are also inconsistent with regard to the association between RHI and HbA1c.[25–27, 31, 33, 34] The present study provides reliable longitudinal assessments of HbA1c, in many cases annually since diagnosis. The resulting measure of glycemic burden, however, was not associated with RHI. Inherent strengths of this study include the prospective design and several longitudinal measurements of HbA1c for each patient. Major limitations are the small number of study subjects, particularly controls with baseline values, and the lack of serial measurements of RHI. In conclusion, we did not find reduced endothelial function, as measured by EndoPAT, in young adults with T1D compared with healthy controls. Furthermore, we did not find any gender difference or significant associations with traditional cardiovascular risk factors or glycemic burden. These results suggest that EndoPAT has limited value in CVD risk assessment in young adults with T1D, but larger and longitudinal studies are needed.

Dataset for endothelial function.

(XLSX) Click here for additional data file.
  34 in total

Review 1.  Assessment of flow-mediated dilation in humans: a methodological and physiological guideline.

Authors:  Dick H J Thijssen; Mark A Black; Kyra E Pyke; Jaume Padilla; Greg Atkinson; Ryan A Harris; Beth Parker; Michael E Widlansky; Michael E Tschakovsky; Daniel J Green
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-15       Impact factor: 4.733

2.  Endothelial function assessment in atherosclerosis: comparison of brachial artery flow‑mediated vasodilation and peripheral arterial tonometry.

Authors:  Grzegorz Wilk; Grzegorz Osmenda; Paweł Matusik; Daniel Nowakowski; Barbara Jasiewicz-Honkisz; Adam Ignacak; Marta Cześnikiewicz-Guzik; Tomasz J Guzik
Journal:  Pol Arch Med Wewn       Date:  2013-09-11

3.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.

Authors:  J A Suwaidi; S Hamasaki; S T Higano; R A Nishimura; D R Holmes; A Lerman
Journal:  Circulation       Date:  2000-03-07       Impact factor: 29.690

4.  Adolescents and young adults with type 1 diabetes display a high prevalence of endothelial dysfunction.

Authors:  A E Scaramuzza; F Redaelli; E Giani; M Macedoni; V Giudici; A Gazzarri; A Bosetti; L De Angelis; G V Zuccotti
Journal:  Acta Paediatr       Date:  2015-02       Impact factor: 2.299

5.  Relation of brachial and digital measures of vascular function in the community: the Framingham heart study.

Authors:  Naomi M Hamburg; Joseph Palmisano; Martin G Larson; Lisa M Sullivan; Birgitta T Lehman; Ramachandran S Vasan; Daniel Levy; Gary F Mitchell; Joseph A Vita; Emelia J Benjamin
Journal:  Hypertension       Date:  2011-01-24       Impact factor: 10.190

Review 6.  Endothelial dysfunction in diabetes.

Authors:  A S De Vriese; T J Verbeuren; J Van de Voorde; N H Lameire; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

7.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.

Authors:  D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

8.  Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study.

Authors:  Hanna Dis Margeirsdottir; Knut Haakon Stensaeth; Jakob Roald Larsen; Cathrine Brunborg; Knut Dahl-Jørgensen
Journal:  Diabetes Care       Date:  2010-06-08       Impact factor: 19.112

9.  Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes.

Authors:  S P Laing; A J Swerdlow; S D Slater; A C Burden; A Morris; N R Waugh; W Gatling; P J Bingley; C C Patterson
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

10.  Altered endothelial function in asymptomatic male adolescents with type 1 diabetes.

Authors:  Farid H Mahmud; Micheal G Earing; Robert A Lee; Aida N Lteif; David J Driscoll; Amir Lerman
Journal:  Congenit Heart Dis       Date:  2006-05       Impact factor: 2.007

View more
  5 in total

Review 1.  Cardiovascular disease in type 1 diabetes.

Authors:  Harish Sharma; Mauro Lencioni; Parth Narendran
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-02-13

2.  Correction: Preserved endothelial function in young adults with type 1 diabetes.

Authors: 
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

3.  Early Endothelial Dysfunction in Type 1 Diabetes Is Accompanied by an Impairment of Vascular Smooth Muscle Function: A Meta-Analysis.

Authors:  Elodie Lespagnol; Luc Dauchet; Mehdi Pawlak-Chaouch; Costantino Balestra; Serge Berthoin; Martin Feelisch; Matthieu Roustit; Julien Boissière; Pierre Fontaine; Elsa Heyman
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-17       Impact factor: 5.555

4.  Increased Intraplatelet ADMA Level May Promote Platelet Activation in Diabetes Mellitus.

Authors:  Jakub Gawryś; Jerzy Wiśniewski; Ewa Szahidewicz-Krupska; Damian Gajecki; Julia Leśniewska; Filip Majda; Karolina Gawryś; Paulina Fortuna; Piotr Mlynarz; Adrian Doroszko
Journal:  Oxid Med Cell Longev       Date:  2020-09-29       Impact factor: 6.543

5.  Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study.

Authors:  Bo Kyung Koo; Woo-Young Chung; Min Kyong Moon
Journal:  Cardiovasc Diabetol       Date:  2020-06-13       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.